

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 November 2002 (14.11.2002)


PCT

(10) International Publication Number  
WO 02/089942 A1

- (51) International Patent Classification<sup>7</sup>: B01D 9/00, 9/02
- (21) International Application Number: PCT/GB02/02006
- (22) International Filing Date: 2 May 2002 (02.05.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
GB 0127380.4 15 November 2001 (15.11.2001) GB
- (71) Applicant (for all designated States except US): ACCENTUS PLC [GB/GB]; 329 Harwell, Didcot, Oxfordshire OX11 0QJ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BOWE, Michael, Joseph [GB/GB]; 17 Balmoral Road, New Longdon, Preston, Lancashire PR4 4JJ (GB). MCCAUSLAND, Linda, Jane [GB/GB]; 20 Shepherd Gardens, Abingdon, Oxfordshire OX14 5PR (GB). STAIRMAND, John, William [GB/GB]; Firdale, 1 School Lane, Guildon Sutton, Chester, Cheshire CH3 7ET (GB).
- (74) Agents: MANSFIELD, Peter, Turquand et al.; c/o Accentus plc, Patents Dept., 329 Harwell, Didcot, Oxfordshire OX1 0QJ (GB).
- (54) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,

[Continued on next page]

(54) Title: FORMATION OF SMALL CRYSTALS



(57) Abstract: Small crystals are made by mixing a solution of a desired substance with an anti-solvent in a fluidic vortex mixer in which the residence time is less than 1 s, for example 10 ms. The liquid within the fluidic vortex mixer (12) is subjected to high intensity ultrasound from a transducer (20, 22) in or on the wall of the mixer, or coupled to a pipe supplying liquid to the mixer. The solution very rapidly becomes supersaturated, and the ultrasound can induce a very large number of nuclei for crystal growth. Small crystals, for example less than 5  $\mu\text{m}$ , are formed that may be of a suitable size for use in inhalers.

WO 02/089942 A1



SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG) of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- 1 -

Formation of Small Crystals

This invention relates to an apparatus and a process for making small crystals, preferably but not exclusively  
5 crystals of size less than 10  $\mu\text{m}$ .

The control of crystal and precipitate particle size and morphology is very important in some circumstances, in particular in the pharmaceutical and agro-chemical  
10 industries in which the final product form is a fine powder. The way in which an active ingredient behaves, whether in the body or upon the surface of a leaf for example, depends critically upon the particle size of the product, and the particular crystal form. Small  
15 particles may be made by processes such as milling, but such processes may have a detrimental effect on the material properties and may also produce a significant proportion of particles which are too small for the desired use, so that crystallisation of crystals in the  
20 desired size range directly from a solution would be desirable.

For many years it has been known to bring about crystallisation by mixing a solvent containing a product  
25 to be crystallised with an anti-solvent, so that after mixing the solution is supersaturated and crystallisation occurs. GB 2 341 120 A describes a system in which the mixing utilizes a fluidic vortex mixer, and in which the emerging mixture is supplied directly to a precipitate  
30 entrapment device. The term anti-solvent means a fluid which promotes precipitation from the solvent of the product (or of a precursor for the product). The anti-solvent may comprise a cold gas, or a fluid which promotes the precipitation via a chemical reaction, or  
35 which decreases the solubility of the product in the solvent; it may be the same liquid as the solvent but at

- 2 -

a different temperature, or it may be a different liquid from the solvent. EP 0 449 454 A (= GB 2 242 376) describes a system for bringing about on-line precipitation in which liquid reagents are thoroughly  
5 mixed using a fluidic vortex mixer, the mixture then being passed through a vessel comprising linked vortex cells in which a pulsed flow ensures a well-defined residence time, hence ensuring particles of a selected mean size are created. The benefits of applying intense  
10 ultrasound during a crystallisation process have also been recognized, for example as described in an article by Chris Price in Pharmaceutical Technology Europe, October 1997, as such insonation can be used to initiate nucleation, so overcoming the problems that can arise  
15 from supersaturation. WO 00/38811 indicates that rapid precipitation, for example by mixing a solution with an anti-solvent, is difficult to control; they describe a process for preparing crystalline particles in which liquids are mixed in a continuous flow cell in the  
20 presence of ultrasonic radiation. The flow cell is substantially cylindrical, with diametrically opposed inlets near the base, and one or more outlet ports at different heights above the base (giving different residence times and hence different particle sizes), the  
25 liquid being mixed by stirring and preferably without inducing any vortex effects.

Surprisingly, it has now being found that very desirable results can be obtained by applying insonation  
30 while mixing a solution of a desired substance with an anti-solvent in a fluidic vortex mixer in which the residence time is less than 1 s. Accordingly, the present invention provides a method of performing crystallisation in which fluids are mixed to cause  
35 precipitation or crystallisation by passage through a fluidic vortex mixer, in which the fluids within the

- 3 -

fluidic vortex mixer are subjected to high intensity ultrasound.

A fluidic vortex mixer comprises a vortex chamber  
5 with two or more peripheral inlets, at least one of which  
is substantially tangential, and with an axial outlet.  
Such a device can achieve very rapid and thorough mixing  
in a very short space of time; for example the residence  
time in the mixer may be less than 0.5 s, or even less  
10 than 0.1 s, for example 20 ms or 10 ms, though usually at  
least 1 ms. The chamber is substantially cylindrical, and  
contains no baffles to disrupt the vortex flow. Such a  
fluidic mixer can therefore achieve a very high degree of  
supersaturation when mixing a saturated solution with an  
15 antisolvent, because of the rapid and very thorough  
mixing.

If a liquid is subjected to an ultrasonic intensity  
above about  $0.3 \text{ W/cm}^2$ , then there is a significant  
20 deposition of energy into the liquid through attenuation  
and non-linear effects. This can be associated with  
cavitation, in which small bubbles are created which are  
filled with vapour or gas, and which collapse rapidly  
during the compression half-cycle of the ultrasonic wave.  
25 Cavitation may lead to temperature transients, and  
pressure transients, and can enhance the rate of  
crystallisation by enhancing nucleation. Indeed, the  
effects of such high intensity ultrasound may be referred  
to as sonochemistry, or more specifically as  
30 sonocrystallisation.

Hence, when mixing a saturated solution with an  
antisolvent, the solution rapidly becomes highly  
supersaturated and the ultrasound can induce a very large  
35 number of nuclei for crystal growth. Not only does the  
high intensity ultrasound induce nucleation in the

- 4 -

supersaturated liquid created by the fluidic vortex mixer, but it also can be expected to suppress the formation of agglomerates of small crystals, and also to inhibit or eliminate fouling of the surfaces of the mixer and adjacent ducts by crystal growth on those surfaces. Hence this process can enable crystals of a material to be formed which are less than 10  $\mu\text{m}$  in size, for example less than 5  $\mu\text{m}$  or less than 1  $\mu\text{m}$ . Such small crystals may be of a suitable size for use in inhalers.

10

The ultrasound may be supplied by a probe extending into the vortex chamber of the fluidic vortex mixer so as to ensure that the entire volume of the vortex chamber is insonated with ultrasound. Alternatively an ultrasonic transducer may be coupled to a wall of the vortex chamber so that ultrasound is transmitted through the wall into the vortex chamber. And in another alternative, ultrasonic transducers may be arranged to subject the liquid streams supplied to the vortex mixer, or the liquid mixture emerging from the vortex mixer, to ultrasonic insonation in such a way that ultrasound propagates through the liquids and pipes carrying those liquids into the vortex mixer. In addition, ultrasonic transducers may be arranged to subject the mixture emerging from the fluidic vortex mixer to intense ultrasonic insonation.

To ensure that the crystal size distribution is not significantly altered by crystal ripening after the crystals leave the mixer it may be desirable to generate a spray of small droplets each containing a single crystal at the outlet of the vortex mixer. This may be aided by introducing a gas such as air, nitrogen or argon into the fluidic mixer to be mixed with the other fluids. Such a spray of droplets can be dried (as in a spray dryer).

- 5 -

The beneficial results obtainable with a fluidic vortex mixer may also be obtainable with other rapid-mixing devices that have no moving parts, such as opposed  
5 jet mixers and Y-junction mixers.

The invention will now be further and more particularly described, by way of example only, and with reference to the accompanying drawings, in which:

10

Figure 1 shows a longitudinal sectional view of a crystallisation apparatus;

Figure 2 shows a transverse sectional view on the  
15 line 2-2 of figure 1;

Figure 3 shows a modification to the apparatus of figure 1;

20 Figure 4 shows another modification to the apparatus of figure 1;

Figure 5 shows a modification to the apparatus of figure 4;  
25

Figure 6 shows a modification to the apparatus of figure 1;

Figure 7 shows particle size distributions for  
30 crystals made in two different ways; and

Figure 8 shows a crystallisation apparatus incorporating modifications to the apparatus of figure 6.

35 Referring now to figure 1, a crystallisation apparatus 10 comprises a vortex mixer 12 including a

- 6 -

cylindrical chamber 14 of diameter 15 mm with an axial outlet 16 at the centre of an end wall, and with four tangential inlets 18 (only two of which are shown in figure 1) around its periphery. A saturated solution S of a desired substance is supplied to two inlets 18, and an anti-solvent A is supplied to the alternate two inlets, as indicated in figure 2. An ultrasonic probe 20 is mounted at the centre of the other end wall and projects into the middle of the chamber 14, its other end being connected to a 300 kHz transducer 22, so the position on the probe 20 at which it is sealed to the wall is a node when the transducer 22 is energised. The outlet 16 communicates with a product receiver vessel 24, an array of 20 kHz ultrasonic transducers 26 being mounted on the outside of the wall of the vessel 24.

Thus in use of the apparatus 10, the saturated solution S is thoroughly and rapidly mixed with the anti-solvent A, the volume of the chamber 14 and the flow rates being such that the residence time in the chamber 14 is for example 10 ms. The ultrasonic energy from the probe 20 insonates the entire volume of the chamber 14 with sufficient intensity to cause nucleation, as localized cavitation occurring on a microscopic scale promotes changes in fluid temperature and pressure that induce nucleation (and also promote formation of the most stable polymorph). By adjusting the power of the ultrasound, and the residence time in the chamber 14, the degree of nucleation can therefore be controlled. The ultrasound has the additional benefit that any crystal deposits within the chamber 14 tend to be removed from the surfaces. Within the receiver vessel 24 the crystal growth process is completed, the ultrasound from the transducers 26 breaking up any crystal agglomerations and preventing surface fouling.



- 7 -

It will be appreciated that the solvent in the solution S and the anti-solvent A must be selected as suitable for a particular substance. Preferably they are miscible with each other. As examples, in some cases the solvent might be acetone, and the anti-solvent be water; or the solvent might be methanol and the anti-solvent be water; or the solvent might be dimethyl formamide and the anti-solvent be water. The selection of appropriate solvent and anti-solvents must be made in accordance with the substance to be crystallised.

Referring to figure 3, in a modification to the apparatus 10 the product receiver vessel is a flow-through ultrasound cell 28 with an ultrasonic probe 30 mounted internally, concentrically within the cell 28, coupled to a transducer 32 outside the cell 28.

Referring now to figure 4, in another modification to the apparatus 10 there is no ultrasonic transducer in or on the vortex mixer 12, and the product receiver vessel 24 is slightly larger than that shown in figure 1 and so has more transducers 26. Each of the pipes 18 carrying the solution S and the anti-solvent A into the vortex mixer 12 incorporates a respective ultrasonic flow-through cell 35 with an ultrasonic probe 36 mounted concentrically within the cell 35 and coupled to a transducer 37 outside the cell 35. This operates in substantially the same way as the apparatus of figure 1, in that the ultrasound from the probes 36 propagates through the pipes 18 into the vortex mixer 12 where it promotes nucleation and reduces fouling. The arrangement provides plug flow conditions which controls residence time to provide a further control on crystal growth and particle size.

Referring now to figure 5 there is shown a

- 8 -

modification to the apparatus of figure 4 (that would be equally applicable to the apparatus 10 of figure 1), the modification being that the product receiver vessel 24 is provided with a draft tube 40, that is to say a

5 concentric open-ended tube within the vessel 24. The outflow from the vortex mixer 12 causes liquid to flow downwardly through the draft tube 40, and there is a consequential recirculation with liquid flowing upwardly outside the draft tube 40. The ultrasonic transducers 26

10 subject the recirculating liquid to intense ultrasound, so reducing fouling and breaking up agglomerations; the back-mixed recirculating liquid may lead to growth of larger crystals, as recirculating crystals contact supersaturated liquid emerging from the mixer 12. These

15 arrangements provide a back mixed environment suitable for the promotion of crystal growth.

Referring now to figure 6 there is shown an alternative modification to the apparatus 10 of figure 1

20 (that would be equally applicable to the apparatus of figure 4) in which an ultrasonic transducer 44 is mounted on the outside of the end wall of the vortex chamber 14 of the fluidic vortex mixer 12. This is particularly suitable with a vortex mixer 12 of diameter above say 20

25 mm; for example the vortex mixer 12 in this embodiment might be of internal diameter 50 mm. As with the crystallisation apparatus 10 of figure 1, during operation the transducer 44 is continuously energised so that the liquid experiences intense insonation as the

30 solution becomes supersaturated. In this embodiment the outflow from the vortex mixer 12 feeds directly into an open-topped holding vessel 46 including a stirrer 47 and with an array of ultrasonic transducers 48 attached to its wall. It will be appreciated that if the crystal

35 growth process is slow the outlet from the vessel 46 may be supplied to a pulsed flow reactor comprising linked

- 9 -

vortex cells in which a pulsed flow ensures a well-defined residence time, as described in GB 2 242 376 B or as described in WO 00/29545; as in the holding vessel 46, each vortex cell in such a pulsed flow reactor may be  
5 supplied with wall-mounted transducers to suppress agglomeration and prevent fouling. Such transducers may be energized continuously to encourage formation of small crystals, or in short bursts intermittently where larger crystals are required.

10

In an alternative mode of operation, if the enhanced nucleation is not required, then the transducer 44 might be energized only if fouling occurs within the vortex mixer 12. The presence of such fouling may be detected  
15 by measuring the pressure drop between the inlet and outlet of the mixer 12.

In the examples above, the mixture of liquids and crystals generated in the fluidic vortex mixer 12 is fed  
20 into a receiver vessel 24, 28 or 46 in which the crystal growth process is completed, ultrasonic irradiation preventing crystal agglomeration during this stage. The crystals initially formed in the mixture are small, and have a narrow size distribution. There is a risk that  
25 crystal ripening may occur in the receiver vessel, with the larger crystals growing at the expense of the smaller crystals, which re-dissolve. It may therefore be preferable to omit the receiver vessel 24, 28 or 46, and instead to spray the mixture to form an aerosol. The  
30 droplets in the aerosol can then be dried to form a powder of small crystals.

The fluidic vortex mixer may differ from that described above, for example having a chamber of diameter  
35 8 mm, with a conical recess in one end wall leading to an axial outlet of diameter 0.8 mm, and with three equally-

- 10 -

spaced tangential inlets around the periphery. As in figure 6, a transducer 44 (of frequency say 50 kHz) is attached to the other end wall of the chamber. The solution S and the anti-solvent A are supplied to two of the tangential inlets, while a gas such as compressed air is supplied to the third tangential index. The resulting spray forms an aerosol that can be dried.

Referring now to figure 7, the crystal size distribution (marked F) is shown for crystals of a pharmaceutical product driven out of solution by an anti-solvent (drowning out crystallisation), using such a fluidic vortex mixer. For comparison the size distribution obtained with a stirred tank reactor is also shown, marked T. In the case of the fluidic mixer, crystals were trapped onto a filter paper using a vacuum pump from the spray emerging from the vortex mixer, to provide a sample. It will be observed that the fluidic vortex mixer gives a very narrow size distribution (about 3.0-4.5  $\mu\text{m}$ ), whereas the stirred tank gives a far broader size spectrum (about 3  $\mu\text{m}$  to 30  $\mu\text{m}$ ).

Referring now to figure 8 a crystallisation apparatus 50 is shown with some similarities to that of figure 6. A vortex mixer 12 carries an externally mounted ultrasonic transducer 44. A hot saturated solution S of a material whose solubility increases with temperature is supplied to the vortex mixer 12. In this example the anti-solvent A is a compressed inert gas (such as nitrogen). The outlet from the vortex mixer 12 feeds into a closed separation chamber 52 with an outlet 53 at its base for a suspension of crystals in liquid, and an outlet 54 near the top for gas and solvent vapour. The outlet 54 communicates via a compressor 56 to a high-pressure storage vessel 58 from which the compressed gas is fed into the vortex mixer 12. Solvent vapour that

- 11 -

condenses in the vessel 58 may be recycled. The mixer 12 is designed to operate with a significant pressure drop so that the inert gas expands and cools (as a result of the Joule-Thompson effect). Cooling also occurs as a result of evaporation of solvent into the gas. The combination of cooling and increasing concentration rapidly generates a supersaturated solution, while the application of ultrasound from the transducer 44 promotes crystal nucleation in a uniform and controlled manner. Ultrasonic transducers 26 are preferably also mounted upon the walls of the separation chamber 52 to suppress agglomeration and prevent fouling.

In a modification to the apparatus of figure 8, the vortex mixer 12 on which the transducer 44 is mounted, and to which a saturated solution and an anti-solvent are supplied, sprays the mixture directly into a spray dryer.

In the spray dryer the droplets containing crystals are contacted by a stream of hot gas, so both the anti-solvent and the solvent evaporate. Hence a fine solid product is produced. Ultrasonic transducers may be mounted on the walls of the spray dryer to generate ultrasonic waves in the gas, to prevent the fine particles from agglomerating.

It should be appreciated that a crystallisation apparatus of the invention may differ from those described above. In particular the frequency of the ultrasonic transducers may be in the range say 20 kHz to 1 MHz. Where the transducer probe projects through a wall into the vortex chamber (as in figure 1), the frequency is desirably selected in accordance with the dimensions of the cell and of the probe so the probe is sealed to the wall at a nodal point. If, as in figure 6, the ultrasonic transducer is coupled to the outside of the wall of the vortex chamber, it will be appreciated

- 12 -

that instead one or more transducers might be coupled to the curved side wall of the vortex chamber rather than to the flat end wall; this is more appropriate for larger vortex chambers of height in excess of 15 mm.

5

It will also be understood that a crystallisation apparatus of the invention may be suitable for use in crystallising a wide variety of different compounds. Some materials for which this crystallisation procedure and apparatus would be useful, in order to provide a narrow particle size distribution and so to help control bio-availability, are: analgesics such as codeine; anti-allergens such as sodium cromoglycate; antibiotics such as penicillin, cephalosporins, streptomycins, or  
15 sulphonamides; antihistamines; anti-inflammatories; bronchodilators; or therapeutic proteins and peptides. This list is not intended to be exhaustive, as the invention is applicable to substantially any crystallisation process. Other possible compounds would  
20 be amino-alcohols, pectins, and complex sugars. Other contexts in which the size distribution and mean size of particles and their morphology are important to the use of the material include dyes and pigments such as azo compounds, and photo-chromatic compounds, and the  
25 production of some catalyst materials.

For example potassium penicillin G may be precipitated from solution in n-butyl acetate using an alkaline anti-solvent such as potassium hydroxide or  
30 potassium acetate solution. A further benefit in this case is that the intense mixing in the presence of ultrasound inhibits the creation of localized regions of high-pH, in which the base-catalysed formation of the impurity penicilloic acid may occur. The more uniform  
35 size distribution is desirable in this case, as is the suppression of fouling.

- 13 -

As another example, a range of different amino acids and proteins may be precipitated. For example pectins can be precipitated from an aqueous solution using an ethanol anti-solvent, and possibly also adjustment of pH. Complex sugars such as glucosamine may also be precipitated, in this case the crystallisation preferably being performed primarily by cooling, for example using an apparatus as described in figure 8 in which the anti-solvent is an inert gas such as nitrogen arranged to cause cooling of the solution. Other sugar-related compounds such d-maltose, sucrose, and d-cellobiose can be crystallised in a similar way: these compounds dissolve in hot water, but do not readily crystallise when cooled (a saturated solution at 50°C will not form crystals even when cooled to 20°C and left for 24 hours), but form small crystals in the presence of ultrasound, for example with the apparatus as in figure 8.

- 14 -

Claims

1. A method of performing crystallisation in which fluids (A, S) are mixed to cause precipitation or  
5 crystallisation by passage through a fluidic vortex mixer (12), in which the fluids within the fluidic vortex mixer (12) are subjected to high intensity ultrasound.
2. A method as claimed in claim 1 wherein the residence  
10 time of the fluids (A, S) in the fluidic vortex mixer (12) is less than 0.1 s.
3. A method as claimed in claim 1 or claim 2 wherein the ultrasound is supplied by a probe (20) extending into  
15 the vortex chamber (14) of the fluidic vortex mixer (12).
4. A method as claimed in claim 1 or claim 2 wherein an ultrasonic transducer (44) is coupled to a wall of the vortex chamber (14) so that ultrasound is transmitted  
20 through the wall into the vortex chamber (14).
5. A method as claimed in any one of the preceding claims wherein ultrasonic transducers (36, 26) are arranged to subject the liquid streams (A, S) supplied to  
25 the vortex mixer (12), or the liquid mixture emerging from the vortex mixer (12), to ultrasonic insonation in such a way that ultrasound propagates through the liquids and pipes carrying those liquids into the vortex mixer (12).
- 30 6. A method as claimed in any one of the preceding claims wherein a gas is also mixed with the fluids (A, S) within the fluidic vortex mixer (12).
- 35 7. A method as claimed in any one of the preceding claims wherein the fluids emerging from the fluidic



- 15 -

vortex mixer (12) are sprayed into a drying zone.

8. An apparatus for performing a method as claimed in any one of the preceding claims.

Fig.1.




Fig.3.





Fig.2.

2/4

Fig.4.





Fig.5.



3/4

Fig.6.






Fig.8.



4/4

Fig.7.



## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB 02/02006

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 B01D9/00 B01D9/02		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 B01D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 38811 A (THEOPHILUS ANDREW LEWIS ;GLAXO GROUP LTD (GB); SINGH HARDEV (GB);) 6 July 2000 (2000-07-06) cited in the application the whole document	1-8
A	GB 2 341 120 A (AEA TECHNOLOGY PLC) 8 March 2000 (2000-03-08) cited in the application the whole document	1-8
A	EP 0 449 454 A (ATOMIC ENERGY AUTHORITY UK) 2 October 1991 (1991-10-02) cited in the application the whole document	1-8
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family		
Date of the actual completion of the international search 30 July 2002		Date of mailing of the international search report 06/08/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2200 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Hilt, D

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 02/02006

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0038811 A	06-07-2000	AU 1877100 A	31-07-2000
		BR 9916587 A	25-09-2001
		CN 1335787 T	13-02-2002
		CZ 20012331 A3	13-03-2002
		EP 1144065 A1	17-10-2001
		WO 0038811 A1	06-07-2000
		NO 20013039 A	22-08-2001
		TR 200101845 T2	22-10-2001
GB 2341120 A	08-03-2000	NONE	
EP 0449454 A	02-10-1991	AU 630286 B2	22-10-1992
		AU 7380091 A	03-10-1991
		CA 2038664 A1	30-09-1991
		DE 69107229 D1	23-03-1995
		DE 69107229 T2	29-06-1995
		EP 0449454 A2	02-10-1991
		GB 2242376 A ,B	02-10-1991
		JP 3261139 B2	25-02-2002
		JP 4222607 A	12-08-1992
		KR 169988 B1	15-01-1999
		NO 911245 A	30-09-1991
		US 5855776 A	05-01-1999
		ZA 9102270 A	24-12-1991